There’s nothing like a $5 billion-plus market to generate a lot of debate. With that much money hanging in the balance, there was already enough incentive to fire up opposing advocates on the sides of (1) bare versus drug-eluting stents, (2) CYPHER versus TAXUS, (3) bypass versus angioplasty/stenting, and countless other polemics without the results [...]
A recent article in The Lancet (”Promoting Healthy Scepticism of Health Statistics,” by Tim Parsons, Public Affairs Office, Johns Hopkins Bloomberg School of Public Health, Baltimore) pointed up the need to understand how specific statistics have been compiled, who the sources are and what the potential biases may be in order to make good decisions [...]
MedMarket Outlook:
Medical Technologies Not Always Perfect but Always Getting Better
There is an inherent nature to medical technologies, as we’ve discussed before, that distinguishes them, sometimes negatively but (it seems) more often positively, and that is that medical technologies are fundamentally focused on symptoms. While this blunt targeting of the manifestation of a disease or disorder [...]
There has not yet been any evidence to suggest that the $5 billion worldwide juggernaut, otherwise known as the market for drug-eluting stents, had any risk of imploding over the increased risk of clots following implantation. However, as we predicted, the occurence of late-stage thrombosis associated with drug-eluting stents is having a de facto impact on this market, even if [...]
The terms “sealant” and “glue” tend to be used interchangeably in the surgical context, but in fact there is a difference in adhesive strength between sealants, pioneered by fibrin products (sometimes homemade) and the later, stronger glues of which cyanoacrylate-based products were the leaders.
Fibrin sealants represented a revolution in local hemostatic measures for both bleeding [...]
